Study:
A Randomized, Double-Blinded, Placebo-Controlled Trial of Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-Line Chemotherapy
Rationale:
n/a
Purpose:
The purpose of this study is to determine if an investigational cell therapy called Cvac can
help prevent EOC from returning when administered to patients who are in complete remission
after surgical removal of their tumor followed by standard first-line chemotherapy.
Following surgery and study randomization, patients will undergo leukapheresis for
manufacture of the study agent and then begin first-line chemotherapy. After completion of
chemotherapy and confirmation of complete remission, patients will enter the treatment phase
of the study.
Study Status: Recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Epithelial Ovarian Cancer |
Biological: Placebo Study Agent
Biological: Cvac |
Phase 2/Phase 3 |
Verified by
Prima BioMed Ltd
May, 2013
Sponsored by: Prima BioMed Ltd
Information provided by: Prima BioMed Ltd
ClinicalTrials.gov identifier: NCT01521143
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States
n/a